Bioequivalence clinical trials

Explore recruiting bioequivalence clinical trials.

Recruiting bioequivalence studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Bioequivalence trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Etude de bioéquivalence entre Circadin et Melatonin PILEJE LP 2 mg

France

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A Randomized Open-label, Single Dose, 3-Period, 6-Sequence, Cross-Over Trial with Washout Periods of at least 14 days to Investigate the Relative Bioavailability of Apraglutide in Dual Chamber Syringes Versus the Reference Formulation in Vials Following Subcutaneous Administrations in Healthy Subjects

Netherlands

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Bioequivalence of Ulipristal Acetate 30 mg Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.

Portugal

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept

Norway

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteers

Poland

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS

Norway

Therapeutic use (Phase IV) EU CTIS Study details

Bioequivalence trials by city

Bioequivalence in Toronto Bioequivalence in Vancouver Bioequivalence in Montreal Bioequivalence in Calgary Bioequivalence in Edmonton Bioequivalence in Ottawa Bioequivalence in Winnipeg Bioequivalence in Quebec City Bioequivalence in Hamilton Bioequivalence in Kitchener Bioequivalence in London Bioequivalence in Halifax Bioequivalence in New York Bioequivalence in Los Angeles Bioequivalence in Chicago Bioequivalence in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease